These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36580025)

  • 1. A multicenter, real-world experience with recombinant FXIII for the treatment of patients with FXIII deficiency: from pharmacokinetics to clinical practice. The Italian FXIII Study.
    Zanon E; Pasca S; Sottilotta G; Molinari AC; Ferretti A; Di Gregorio P; Pollio B; Pizzuti M; Notarangelo LD; Biasoli C; Cojutti P; Pea F; Simioni P; Peyvandi F
    Blood Transfus; 2023 Jul; 21(4):350-355. PubMed ID: 36580025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of recombinant factor XIII in young children with congenital FXIII deficiency and comparison with older patients.
    Williams M; Will A; Stenmo C; Rosholm A; Tehranchi R
    Haemophilia; 2014 Jan; 20(1):99-105. PubMed ID: 23834599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics of recombinant FXIII (catridecacog) from the MENTOR
    Pasca S; PierGiorgio C; Pea F;
    J Thromb Thrombolysis; 2022 Nov; 54(4):593-596. PubMed ID: 36094687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant factor XIII prophylaxis is safe and effective in young children with congenital factor XIII-A deficiency: international phase 3b trial results.
    Kerlin BA; Inbal A; Will A; Williams M; Garly ML; Jacobsen L; Kearney SL
    J Thromb Haemost; 2017 Aug; 15(8):1601-1606. PubMed ID: 28581691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-Life Population Pharmacokinetics of Recombinant Factor XIII and Dosing Considerations for Preventing the Risk of Bleeding in Patients with FXIII Congenital Deficiency.
    Cojutti PG; Zanon E; Pasca S; Pea F;
    Clin Pharmacokinet; 2022 Apr; 61(4):505-513. PubMed ID: 34718987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and safety of plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency.
    Nugent DJ; Ashley C; García-Talavera J; Lo LC; Mehdi AS; Mangione A
    Haemophilia; 2015 Jan; 21(1):95-101. PubMed ID: 25458735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of recombinant factor XIII at steady state in patients with congenital factor XIII A-subunit deficiency.
    Kerlin B; Brand B; Inbal A; Halimeh S; Nugent D; Lundblad M; Tehranchi R
    J Thromb Haemost; 2014 Dec; 12(12):2038-43. PubMed ID: 25263390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of prophylactic treatment with plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency.
    Ashley C; Chang E; Davis J; Mangione A; Frame V; Nugent DJ
    Haemophilia; 2015 Jan; 21(1):102-8. PubMed ID: 25377187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic characterization of recombinant factor XIII (FXIII)-A2 across age groups in patients with FXIII A-subunit congenital deficiency.
    Brand-Staufer B; Carcao M; Kerlin BA; Will A; Williams M; Tornøe CW; Sandberg Lundblad M; Nugent D
    Haemophilia; 2015 May; 21(3):380-385. PubMed ID: 25643920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing the First Recombinant Factor XIII for Congenital Factor XIII Deficiency: Clinical Challenges and Successes.
    Carcao M; Fukutake K; Inbal A; Kerlin B; Lassila R; Oldenburg J; Garly ML; Nugent D
    Semin Thromb Hemost; 2017 Feb; 43(1):59-68. PubMed ID: 27556350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency.
    Carcao M; Altisent C; Castaman G; Fukutake K; Kerlin BA; Kessler C; Lassila R; Nugent D; Oldenburg J; Garly ML; Rosholm A; Inbal A
    Thromb Haemost; 2018 Mar; 118(3):451-460. PubMed ID: 29448295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, pharmacokinetics, and immunogenicity of single-dose rFXIII administration to healthy volunteers.
    Reynolds TC; Butine MD; Visich JE; Gunewardena KA; MacMahon M; Pederson S; Bishop PD; Morton KM
    J Thromb Haemost; 2005 May; 3(5):922-8. PubMed ID: 15869585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency.
    Inbal A; Oldenburg J; Carcao M; Rosholm A; Tehranchi R; Nugent D
    Blood; 2012 May; 119(22):5111-7. PubMed ID: 22451421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency.
    Lovejoy AE; Reynolds TC; Visich JE; Butine MD; Young G; Belvedere MA; Blain RC; Pederson SM; Ishak LM; Nugent DJ
    Blood; 2006 Jul; 108(1):57-62. PubMed ID: 16556896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal factor XIII activity level to prevent major spontaneous bleeds.
    Menegatti M; Palla R; Boscarino M; Bucciarelli P; Muszbek L; Katona E; Makris M; Peyvandi F;
    J Thromb Haemost; 2017 Sep; 15(9):1728-1736. PubMed ID: 28688221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and effectiveness of recombinant factor XIII-A
    Poulsen LH; Kerlin BA; Castaman G; Molinari AC; Menegatti M; Nugent D; Dey S; Garly ML; Carcao M
    Res Pract Thromb Haemost; 2022 Feb; 6(2):e12628. PubMed ID: 35243202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tailored prophylaxis with rFXIII (NovoThirteen
    Zanon E; Pasca S; Radu C; Scattolo N; Spiezia L; Simioni P
    Haemophilia; 2019 May; 25(3):e206-e208. PubMed ID: 30888101
    [No Abstract]   [Full Text] [Related]  

  • 18. Factor XIII deficiency enhances thrombin generation due to impaired fibrin polymerization - An effect corrected by Factor XIII replacement.
    Pitkänen HH; Jouppila A; Lemponen M; Ilmakunnas M; Ahonen J; Lassila R
    Thromb Res; 2017 Jan; 149():56-61. PubMed ID: 27902939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of F13A1 gene mutations in 73 patients treated with recombinant FXIII-A
    Ivaškevičius V; Biswas A; Garly ML; Oldenburg J
    Haemophilia; 2017 May; 23(3):e194-e203. PubMed ID: 28520207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catridecacog: a breakthrough in the treatment of congenital factor XIII A-subunit deficiency?
    Korte W
    J Blood Med; 2014; 5():107-13. PubMed ID: 25031548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.